|
⚲
|
| Keyboard |
| Rock Springs Capital Management LP
✚
|
|
|---|---|
| CRD # | 168648 |
| SEC # | 801-78511 |
| CIK # | 0001595725, 0001735397 |
| AUM | 2,426.3 M (2026-03-24) |
| Employees | 17 (47% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 410-220-0130 |
| Address | 650 S Exeter Street Baltimore, MD 21202 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/24/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Compensation Payable to Rock Springs Rock Springs’ compensation for the investment advisory services it provides to the Funds is comprised of, in each case, an asset-based management fee (which is calculated as of the first day of each calendar quarter) and incentive compensation (which is allocated/paid annually in arrears and upon withdrawals and distributions) that is based on the performance achieved for the account of each Investor, subject to a benchmark or a hurdle and high water mark (as applicable), which amounts are deducted from the Form ADV Part 2A | Rock Springs Capital Management LP March 25, 2026 Funds. The fees and expenses applicable to each Fund are set forth in detail in each of the Fund’s Governing Fund Documents. Rock Springs’ fee schedule is omitted because this brochure is only being delivered to qualified purchasers as defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”). Rock Springs’ compensation is negotiable and Rock Springs may, in its sole discretion, elect to waive, reduce or calculate differently any compensation with respect to any person, including partners or employees of Rock Springs or its affiliates, such persons’ family members and trusts or other entities established for the benefit of such persons or their family members (collectively, and together with Rock Springs and its affiliates, “Related Persons”). Organizational, Operating and Other Expenses As a general matter, expenses borne by the Feeder Funds are set forth in the relevant Governing Fund Documents. The Feeder Funds bear all of their organizational, operating and other costs and expenses, as well as indirectly bear their pro rata share of the applicable Master Fund’s organizational, operating and other expenses, including investment-related expenses (e.g., costs and expenses associated with the investigation of investment opportunities (whether or not consummated) (which also includes expenses relating to attendance at medical and industry conferences), research, negotiating, financing, sourcing, acquiring, holding, hedging, settling and disposing of its investments) or other transaction costs, including travel expenses (including, for the avoidance of doubt, research and investigation-related travel (which includes first-class airfare in accordance with Rock Springs’ travel policy)), transaction fees, consulting (e.g., expert network fees), fees and reasonable out-of-pocket expenses incurred by an independent investor representative, advisory, investment banking, legal and other professional fees relating to investments or contemplated investments, the Master Fund’s brokerage commissions, information-related expenses (including costs and expenses associated with Bloomberg, FactSet, market data and market data feeds, vendors of portfolio analytics software (e.g., best execution analytical software) and tools and other similar costs and expenses), clearing and settlement charges, custodial fees, interest expenses, appraisal fees and expenses, expenses, interest charges and costs incurred in connection with any credit facilities, expenses incurred in collection of monies owed to the applicable Fund, legal, auditing and accounting expenses (including, but not limited to, expenses associated with the preparation of the applicable Fund’s financial statements, any tax returns and with respect to Schedules K-1), out-of-pocket costs incurred by Rock Springs (including its counsel) relating to the preparation of regulatory filings or the determination of whether such regulatory filings are necessary, and any other costs associated with such regulatory filings related to the Funds or Rock Springs with respect to the Funds (including, but not limited to Schedules D, F, G and/or 13H filings, Section 16 filings, Form PF filings, Form N-PX, Form SHO and Hart-Scott-Rodino), insurance expenses (including directors’ and officers’ insurance, errors and omissions insurance, cybersecurity insurance and other similar policies), fees and expenses of the Funds’ administrators, organizational expenses, expenses relating to the ongoing offer and sale of interests and withdrawals and transfers thereof, including, but not limited to legal expenses incurred by the Feeder Funds and Rock Springs in amending the Feeder Funds’ confidential offering documents, printing and mailing costs, management fees, any entity-level taxes, fees or other governmental charges levied against the Funds or any special purpose vehicle, all litigation-related and indemnification expenses, wind-up and liquidation expenses, extraordinary expenses and expenses comparable to any of the foregoing. The Feeder Funds also bear their pro rata share of the third-party expenses incurred by the applicable Master Fund in relation to its compliance obligations with respect to applicable anti-money laundering laws or the laws, regulations, and executive Form ADV Part 2A | Rock Springs Capital Management LP March 25, 2026 orders administered by the Treasury Department’s Office of Foreign Assets Control or other laws or regulations by any person in any relevant jurisdiction, including expenses incurred with respect to the preparation of compliance manuals and ongoing training. The Feeder Funds share all items of profit, loss, income and expense of the applicable Master Fund on a pro rata basis in accordance with their respective capital account balances in the Master Fund, unless, in the judgment of Rock Springs, tax, regulatory, legal or other considerations make such pro rata arrangements inappropriate; provided that costs, fees and expenses incurred for the benefit of only a Domestic Fund or an Offshore Fund will be allocated solely to such Domestic Fund or Offshore Fund, respectively. Rock Springs Personnel Compensation All remuneration paid to Rock Springs, the General Partner and their respective principals, officers, ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/24/2026) [Brochure] |
|---|
Item 7: Types of Clients Rock Springs provides investment advisory services to the Funds. Investment advice is provided directly to the Funds, subject to the direction and control of the General Partner, and not individually to the Investors. Investors in the Funds may include, but are not limited to, high net worth individuals, family offices, funds of hedge funds, endowments, foundations, trusts, charitable organizations, pension plans, and corporate or business entities. Details concerning applicable Investor suitability criteria are set forth in the respective Fund’s Governing Fund Documents. The minimum commitment for an Investor is outlined in the respective Fund’s Governing Fund Documents, but is generally $10 million. However, Rock Springs and/or its affiliates maintain discretion to accept less than the minimum investment threshold. Each Investor is required to meet certain suitability qualifications, such as being an “accredited investor” within the meaning set forth in Regulation D under the Securities Act of 1933, as amended, and a “qualified purchaser” as defined in Section 2(a)(51) of the Investment Company Act. Form ADV Part 2A | Rock Springs Capital Management LP March 25, 2026 |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Revolution Medicines Inc | 0.1 | ||
| Lilly Eli & Co | 0.1 | ||
| Synta Pharmaceuticals Corp | 0.1 | ||
| Mirum Pharmaceuticals Inc | 0.1 | ||
| Argenx SE | 0.1 | ||
| Rhythm Pharmaceuticals Inc | 0.1 | ||
| Insmed Inc | 0.1 | ||
| Ascendis Pharma A/S | 0.0 | ||
| Xenon Pharmaceuticals Inc | 0.0 | ||
| Desert Gateway Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Four Pines Master Fund LP | [2020-03-30] | 186.0 M | 311.1 M |
| Filed 2026-03-20 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Rock Springs Capital Master Fund LP | [2014-01-22] | 2,472.6 M | 2,115.2 M |
| Filed 2026-01-21 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 6 | 2.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 6 | 2.4 |
| By Discretionary | ||
| Discretionary | 6 | 2.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 6 | 2.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.6 | |
| United States Persons | 1.9 | |
| Total | 6 | 2.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Kris Jenner | Executive Officer | 7 | 2 | |
| Gordon Bussard | Executive Officer | 4 | 2 | |
| Graham McPhail | Executive Officer | 4 | 2 | |
| Rock Springs Capital Management LP | Executive Officer | 4 | 2 | |
| Rock Springs General Partner LLC | Executive Officer | 2 | 2 | |
| Four Pines General Partner LLC | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001595725] | |
| 3 | [0001595725] | |
| 4 | [0001595725] | |
| SC 13G | [0001595725] | |
| 3 | [0001735397] | |
| 4 | [0001735397] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.3B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 5493004NKG0T3VM7NZ08 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 756,472 | ||
|
Xilio Therapeutics Inc XLO
Series C Preferred Stock · derivative
|
2021-10-26 | Conversion | 7,186,490 | ||
|
Xilio Therapeutics Inc XLO
Series C Preferred Stock · derivative
|
2021-10-26 | Conversion | 1,437,297 | ||
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Buy | 500,000 | $16.00 | 8,000,000 |
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 151,294 | ||
|
Theseus Pharmaceuticals Inc THRX
Series B Convertible Preferred Stock · derivative
|
2021-10-12 | Conversion | 349,320 | ||
|
Theseus Pharmaceuticals Inc THRX
Common Stock
|
2021-10-12 | Buy | 250,000 | $16.00 | 4,000,000 |
|
Theseus Pharmaceuticals Inc THRX
Common Stock
|
2021-10-12 | Conversion | 87,329 | ||
|
Theseus Pharmaceuticals Inc THRX
Common Stock
|
2021-10-12 | Conversion | 349,320 | ||
|
Theseus Pharmaceuticals Inc THRX
Series B Convertible Preferred Stock · derivative
|
2021-10-12 | Conversion | 87,329 | ||
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Conversion | 556,298 | ||
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Buy | 370,000 | $19.00 | 7,030,000 |
|
Verve Therapeutics Inc VERV
Common Stock
|
2021-06-21 | Conversion | 152,926 | ||
|
Verve Therapeutics Inc VERV
Series B Preferred Stock · derivative
|
2021-06-21 | Conversion | 1,416,023 | ||
|
Verve Therapeutics Inc VERV
Series B Preferred Stock · derivative
|
2021-06-21 | Conversion | 5,151,043 | ||
|
Atea Pharmaceuticals Inc AVIR
Series D Convertible Preferred Stock · derivative
|
2020-11-03 | Conversion | 178,063 | ||
|
Atea Pharmaceuticals Inc AVIR
Series D-1 Convertible Preferred Stock · derivative
|
2020-11-03 | Conversion | 104,340 | ||
|
Atea Pharmaceuticals Inc AVIR
Series D Convertible Preferred Stock · derivative
|
2020-11-03 | Conversion | 890,313 | ||
|
Atea Pharmaceuticals Inc AVIR
Common Stock
|
2020-11-03 | Buy | 7,292 | $24.00 | 175,008 |
|
Atea Pharmaceuticals Inc AVIR
Common Stock
|
2020-11-03 | Buy | 242,708 | $24.00 | 5,824,992 |
| showing 20 of 38 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Analog Century Management LP
✚
|
NY | 2,451.6 M |
|
683 Capital Management LLC
✚
|
NY | 2,436.9 M |
|
Long Focus Capital Management LLC
✚
|
PR | 2,436.5 M |
|
Permian Investment Partners LP
✚
|
TX | 2,433.6 M |
|
Dark Forest Capital Management LP
✚
|
NY | 2,417.0 M |
|
CoreCommodity Management LLC
✚
|
CT | 2,413.9 M |
|
Forest Avenue Capital Management LP
✚
|
FL | 2,406.0 M |
|
Kynam Capital Management LP
✚
|
2,405.4 M | |
|
Alatus Capital LLC
✚
|
2,398.4 M | |
|
Heard Capital LLC
✚
|
IL | 2,395.9 M |